


(Rs. in crores except per share data)						
Statement of Consolidated Financial Results for the Quarter and Nine Months Ended 31-Dec-2018						
Particulars	Quarter ended (Unaudited)			Nine Months ended (Unaudited)		Year ended (Audited)
	31-Dec-2018	30-Sep-2018	31-Dec-2017	31-Dec-2018	31-Dec-2017	31-Mar-2018
Revenue						
Net sales	1948	1858	1434	5640	4159	5825
Other operating income	103	36	29	177	83	125
Revenue from operations (net)	2051	1894	1463	5817	4242	5950
Other income	3	10	74	40	257	299
Total revenue	2054	1904	1537	5857	4499	6249
Expenses						
Cost of materials consumed	335	271	260	930	691	1039
Purchases of stock-in-trade	216	238	319	702	707	997
Changes in inventories of finished goods, work-in-progress and stock-in-trade	29	39	(187)	54	(187)	(362)
Employee benefits expense	368	343	272	1057	818	1135
Finance costs	133	126	80	381	187	308
Depreciation and amortisation expense	156	152	94	458	258	409
Other expenses	542	530	440	1563	1228	1792
Total expenses	1779	1699	1278	5145	3702	5318
Profit before tax	275	205	259	712	797	931
Tax expense						
Current Tax	92	72	45	217	145	199
Deferred Tax	(64)	(46)	89	(94)	135	(8)
Short / (excess) provision of earlier periods	1	-	67	1	67	62
Total tax expense	29	26	201	124	347	253
Net Profit for the period	246	179	58	588	450	678
Attributable to :						
- Owners of the company	246	179	58	588	450	678
- Non controlling Interest *	0	0	0	0	0	0
Other Comprehensive Income						
Items that will not be reclassified to profit or loss	(3)	(5)	(2)	(9)	(8)	(0)
Income tax relating to items that will not be reclassified to profit or loss	1	2	1	3	3	2
Items that will be reclassified to profit or loss	178	(125)	29	(20)	(134)	(202)
Income tax relating to items that will be reclassified to profit or loss	(51)	32	(7)	6	42	59
Total other comprehensive income	125	(96)	21	(20)	(97)	(141)
Total Comprehensive Income	371	83	79	568	353	537
Attributable to :						
- Owners of the company	371	83	79	568	353	537
- Non controlling Interest *	0	0	0	0	0	0
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62	84.62	84.62
Other Equity excluding Revaluation Reserves						4537
Earnings per share (of Rs. 5/- each) (not annualised for the quarter):						
Basic	14.50	10.57	3.37	34.73	26.53	40.07
Diluted	14.50	10.57	3.37	34.73	26.53	40.07

* Less than Rs. 1 crore



Notes:

- 1 The above results were reviewed by the Audit and Risk Management Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on 30-Jan-2019. The auditor have carried out review of the above said results. There is no qualification in the auditors report on this statement of financial results.
- 2 The consolidated financial results include the financial results of seventeen wholly owned subsidiaries and one partnership firm with that of the Company.
- 3 The Group operates in a single segment i.e Generic Formulation Business.
- 4 The Parent Company has acquired branded business of Unichem Laboratories Limited for India and Nepal on a going concern basis by way of slump sale on 14-Dec-2017. The quarter and nine months ended 31-Dec-2017 and year ended 31-Mar-2018 includes revenue and expenses (including amortisation and interest) of the acquired business from the date of acquisition.
- 5 Torrent Pharma Inc., wholly owned subsidiary of Parent Company, has acquired 100% equity shares of Bio-Pharm Inc., on 18-Jan-2018. The quarter and nine months ended 31-Dec-2018, quarter ended 30-Sep-2018 and year ended 31-Mar-2018 includes revenue and expenses (including amortisation and interest) of the acquired entity.
- 6 Deferred tax expense during the quarter ended 30-Sep-2018 and nine months ended 31-Dec-2018 includes MAT credit of Rs. 73 crores pertaining to earlier periods.
- 7 (a) The listed Non Convertible Debentures of the Parent Company aggregating Rs. 2048 crores as on 31-Dec-2018 (previous year ended Rs. 1399 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Parent Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
(b) The listed Non Convertible Debentures of the company aggregating Rs. Nil as on 31-Dec-2018 (previous year ended Rs. 1000 crores) to be secured by way of first pari passu charge on certain specified immovable & movable assets and identified trademarks of the Company.
- 8 Effective 1 April 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.
- 9 The Board of Directors in their meeting held on 30-Jan-2019, declared an interim equity dividend of Rs. 13.00 per equity share.
- 10 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED


SAMIR MEHTA
Executive Chairman

Place : Ahmedabad, Gujarat
Date : 30-Jan-2019

